DeepMed Research

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Biological: MEDI528 50 mg
Other: PLACEBO

First Posted Date: 2008-01-11

Last Posted Date: 2014-03-21

Lead Sponsor: MedImmune LLC

Target Recruit Count: 11

Registration Number: NCT00590720

Locations: 🇨🇦
UHN- Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
Northeast Medical Research Associates, Inc, No. Dartmouth, Massachusetts, United States
🇺🇸
Institute of Healthcare Assessment, Inc, San Diego, California, United States

and more 9 locations

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Phase 1

Terminated

Conditions: Leukemia, Prolymphocytic Leukemia, Small
Leukemia, Lymphoma, Chronic Lymphocytic
Lymphocytic Lymphoma, Moxetumomab Pasudotox

Interventions: Drug: CAT-8015 5 mcg/kg
Drug: CAT-8015 10 mcg/kg
Drug: CAT-8015 20 mcg/kg

First Posted Date: 2008-01-07

Last Posted Date: 2017-07-06

Lead Sponsor: MedImmune LLC

Target Recruit Count: 11

Registration Number: NCT00587457

Locations: 🇵🇱
Research Site, Lodz, Poland

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Phase 1

Completed

Conditions: Hairy Cell Leukemia

Interventions: Drug: Moxetumomab Pasudotox (CAT 8015)
Drug: CAT 8015 (Moxetumomab Pasudotox)

First Posted Date: 2008-01-07

Last Posted Date: 2019-04-02

Lead Sponsor: MedImmune LLC

Target Recruit Count: 49

Registration Number: NCT00586924

Locations: 🇵🇱
Research Site, Lodz, Poland

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: CAT-8015

First Posted Date: 2008-01-07

Last Posted Date: 2011-11-22

Lead Sponsor: MedImmune LLC

Target Recruit Count: 50

Registration Number: NCT00587015

Locations: 🇺🇸
Tower Hematology Oncology Medical Group, Beverly Hills, California, United States
🇵🇱
Kalinika Hemotologii Uniwersytetu Medycznego, Lodz, Poland
🇺🇸
NCI, National Institutes of Health, Bethesda, Maryland, United States

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MEDI-557

First Posted Date: 2007-12-21

Last Posted Date: 2011-11-23

Lead Sponsor: MedImmune LLC

Target Recruit Count: 31

Registration Number: NCT00578682

Locations: 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States

A Post Marking Study to Evaluate the Safety of FluMist in Children

Completed

Conditions: Healthy

Interventions: Biological: TIV (Injection)
Biological: FLuMist
Other: Unvaccinated Control

First Posted Date: 2007-12-10

Last Posted Date: 2012-03-08

Lead Sponsor: MedImmune LLC

Target Recruit Count: 29296

Registration Number: NCT00569894

Locations: 🇺🇸
Research Site, Oakland, California, United States

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: MEDI-507
Other: Placebo

First Posted Date: 2007-10-08

Last Posted Date: 2007-11-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 420

Registration Number: NCT00540618

Locations: 🇺🇸
The South Bend Clinic, South Bend, Indiana, United States
🇺🇸
nTouch Research Corporation, San Diego, California, United States
🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States

and more 39 locations

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Phase 2

Completed

Conditions: Congenital Heart Disease

Interventions: Biological: Motavizumab
Biological: Palivizumab

First Posted Date: 2007-10-03

Last Posted Date: 2012-02-16

Lead Sponsor: MedImmune LLC

Target Recruit Count: 1236

Registration Number: NCT00538785

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

and more 142 locations

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma, B-Cell
Lymphoma, Non-Hodgkin

Interventions: Drug: MEDI-538

First Posted Date: 2007-10-02

Last Posted Date: 2008-09-05

Lead Sponsor: MedImmune LLC

Target Recruit Count: 18

Registration Number: NCT00538096

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

Phase 1

Completed

Conditions: DERMATOMYOSITIS OR POLYMYOSITIS

Interventions: Biological: MEDI-545
Other: Placebo

First Posted Date: 2007-09-21

Last Posted Date: 2012-05-28

Lead Sponsor: MedImmune LLC

Target Recruit Count: 51

Registration Number: NCT00533091

Locations: 🇺🇸
Research Site, Duncansville, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy